FREEDOM-3 is a Phase 2 trial exploring the safety and clinical activity of FCR001 in patients with a severe form of scleroderma. Scleroderma is a complex and heterogeneous systemic autoimmune disease affecting multiple tissues and organs. We believe that positive proof of concept data in this trial could support the potential applicability of FCR001 to other severe, systemic autoimmune diseases.

Could you be a part of what’s next for dcSSc?

The FREEDOM-3 clinical trial is researching the safety, tolerability, and effectiveness of a stem cell transplant with an investigational cell therapy in people with rapidly progressing diffuse cutaneous systemic sclerosis (dcSSc; also known as scleroderma) and who are at risk for organ failure.

Take a short survey below to find out if you could qualify.